Home
Storia in 1 fonti
Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
As Legend Biotech became profitable, the company is navigating the next phase of growth for its flagship CAR-T therapy, Carvykti. | As Legend Biotech became profitable, the company is navigating Carvykti's next phase of growth. Taiho and Cullinan's EGFR candidate delivered a phase 3 win. WuXi AppTec won a preliminary injunction against the Defense Department's black list designation. And more.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
Legend interim CEO talks rising competition as Carvykti maker posts first profit
More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter. | Legend Biotech's…
- ·
Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
As Legend Biotech became profitable, the company is navigating the next phase of growth for its flagship CAR-T therapy, Carvykti. | As Legend Biotech became profitable, the…